British Journal of Cancer - Table of Contents alert Volume 107 Issue 4

TABLE OF CONTENTS Volume 107, Issue 4 (585-756) Published online 7 August 2012 In this issue Clinical Studies Translational Therapeutics Molecular Diagnostics Genetics and Genomics Letter to the Editor Corrigendum Also new today Advance online publication Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement British Journal of Cancer presents: Occupational Cancer in Britain Lesley Rushton and Gareth Evans with the British Occupational Cancer Burden Study Group Foreword by Kurt Straif This study aims to provide an objective estimate of the burden of cancer in Britain due to occupation. It presents extensive analyses for all carcinogens and occupational circumstances defined as relevant by IARC. The results should help the development of an evidence-based approach for occupational cancer control. Read the articles for FREE   Clinical Studies Top A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications P G Corrie, R Bulusu, C B Wilson, G Armstrong, S Bond, R Hardy, S Lao-Sirieix, D Parashar, A Ahmad, F Daniel, M Hill, G Wilson, C Blesing, A M Moody, K McAdam and M Osborne Br J Cancer 2012 107: 585-587; advance online publication, July 19, 2012; 10.1038/bjc.2012.318 Abstract | Full Text Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients U Wagner, C Marth, R Largillier, J Kaern, C Brown, M Heywood, T Bonaventura, I Vergote, M C Piccirillo, R Fossati, V Gebski and E P Lauraine Br J Cancer 2012 107: 588-591; advance online publication, July 26, 2012; 10.1038/bjc.2012.307 Abstract | Full Text Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer C Nabhan, D Villines, T V Valdez, K Tolzien, T M Lestingi, J D Bitran, S M Christner, M J Egorin and J H Beumer Br J Cancer 2012 107: 592-597; advance online publication, July 17, 2012; 10.1038/bjc.2012.312 Abstract | Full Text Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours G Freyer, N Isambert, B You, S Zanetta, C Falandry, L Favier, V Trillet-Lenoir, S Assadourian, K Soussan-Lazard, S Ziti-Ljajic and P Fumoleau Br J Cancer 2012 107: 598-603; advance online publication, July 12, 2012; 10.1038/bjc.2012.304 Abstract | Full Text A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours I Diaz-Padilla, L L Siu, M San Pedro-Salcedo, A R A Razak, A D Colevas, F A Shepherd, N B Leighl, J W Neal, A Thibault, L Liu, J Lisano, B Gao, E B Lawson and H A Wakelee Br J Cancer 2012 107: 604-611; advance online publication, July 17, 2012; 10.1038/bjc.2012.319 Abstract | Full Text Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies M Mandalà, F Grosso, C Vitalini, I Corradino, R Sanfilippo, S Colombini, M Clerici, R Labianca, A De Pascale and S Marsoni Br J Cancer 2012 107: 612-616; advance online publication, July 24, 2012; 10.1038/bjc.2012.325 Abstract | Full Text Online screening for distress, the 6th vital sign, in newly diagnosed oncology outpatients: randomised controlled trial of computerised vs personalised triage L E Carlson, A Waller, S L Groff, L Zhong and B D Bultz Br J Cancer 2012 107: 617-625; advance online publication, July 24, 2012; 10.1038/bjc.2012.309 Abstract | Full Text KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer U Malapelle, C Carlomagno, M Salatiello, A De Stefano, C De Luca, R Bianco, R Marciano, C Cimminiello, C Bellevicine, S De Placido and G Troncone Br J Cancer 2012 107: 626-631; advance online publication, July 17, 2012; 10.1038/bjc.2012.275 Abstract | Full Text Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer K Kaira, Y Sunose, K Arakawa, T Ogawa, N Sunaga, K Shimizu, H Tominaga, N Oriuchi, H Itoh, S Nagamori, Y Kanai, A Segawa, M Furuya, M Mori, T Oyama and I Takeyoshi Br J Cancer 2012 107: 632-638; advance online publication, July 17, 2012; 10.1038/bjc.2012.310 Abstract | Full Text Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study S Sleijfer, T Gorlia, C Lamers, H Burger, J-Y Blay, A Le Cesne, M Scurr, F Collin, L Pandite, S Marreaud and P Hohenberger Br J Cancer 2012 107: 639-645; advance online publication, July 17, 2012; 10.1038/bjc.2012.328 Abstract | Full Text Effect of Paget’s disease of bone (osteitis deformans) on the progression of prostate cancer bone metastasis S-M Tu, A Som, B Tu, C J Logothetis, M-H Lee and S-CJ Yeung Br J Cancer 2012 107: 646-651; advance online publication, July 17, 2012; 10.1038/bjc.2012.315 Abstract | Full Text Translational Therapeutics Top Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer N Kozakai, E Kikuchi, M Hasegawa, E Suzuki, H Ide, A Miyajima, Y Horiguchi, J Nakashima, K Umezawa, N Shigematsu and M Oya Br J Cancer 2012 107: 652-657; advance online publication, July 17, 2012; 10.1038/bjc.2012.321 Abstract | Full Text Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice Y Edrei, E Gross, N Corchia and R Abramovitch Br J Cancer 2012 107: 658-666; advance online publication, July 17, 2012; 10.1038/bjc.2012.322 Abstract | Full Text Molecular Diagnostics Top EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer K Boye, J M Nesland, B Sandstad, M Haugland Haugen, G M Mælandsmo and K Flatmark Br J Cancer 2012 107: 667-674; advance online publication, July 10, 2012; 10.1038/bjc.2012.293 Abstract | Full Text Expression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome Y-Q Zhang, M Pilyugin, D Kuester, V P Leoni, L Li, G Casula, L Zorcolo, R Schneider-Stock, L Atzori and I Irminger-Finger Br J Cancer 2012 107: 675-683; advance online publication, July 19, 2012; 10.1038/bjc.2012.297 Abstract | Full Text Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation J S Hall, J Taylor, H R Valentine, J J Irlam, A Eustace, P J Hoskin, C J Miller and C M L West Br J Cancer 2012 107: 684-694; advance online publication, July 17, 2012; 10.1038/bjc.2012.294 Abstract | Full Text A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer M J Proctor, D C McMillan, D S Morrison, C D Fletcher, P G Horgan and S J Clarke Br J Cancer 2012 107: 695-699; advance online publication, July 24, 2012; 10.1038/bjc.2012.292 Abstract | Full Text Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer T Sasahira, M Kurihara, U K Bhawal, N Ueda, T Shimomoto, K Yamamoto, T Kirita and H Kuniyasu Br J Cancer 2012 107: 700-706; advance online publication, July 26, 2012; 10.1038/bjc.2012.330 Abstract | Full Text Apricoxib upregulates 15-PGDH and PGT in tobacco-related epithelial malignancies M A St John, G Wang, J Luo, M Dohadwala, D Hu, Y Lin, M Dennis, J M Lee, D Elashoff, T Lawhon, S L Zaknoen, F J Burrows and S M Dubinett Br J Cancer 2012 107: 707-712; advance online publication, July 24, 2012; 10.1038/bjc.2012.203 Abstract | Full Text Akt1 mediates prostate cancer cell microinvasion and chemotaxis to metastatic stimuli via integrin β3 affinity modulation A Goc, J Liu, T V Byzova and P R Somanath Br J Cancer 2012 107: 713-723; advance online publication, July 5, 2012; 10.1038/bjc.2012.295 Abstract | Full Text Accurate and rapid novel genetic diagnosis for detection of sentinel lymph node metastasis in breast cancer patients H Iinuma, J Tamura, D Omoto, N Kamo, S Ohnaka, Y Mitoma, Y Miyazawa, K Okinaga, T Imamura, R Fukushima, T Watanabe and T Ikeda Br J Cancer 2012 107: 724-731; advance online publication, July 10, 2012; 10.1038/bjc.2012.300 Abstract | Full Text Genetics and Genomics Top Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse C Palmieri, M Monteverde, L Lattanzio, O Gojis, B Rudraraju, M Fortunato, N Syed, A Thompson, O Garrone, M Merlano, C Lo Nigro and T Crook Br J Cancer 2012 107: 732-738; advance online publication, July 10, 2012; 10.1038/bjc.2012.308 Abstract | Full Text Lipoprotein lipase is frequently overexpressed or translocated in cervical squamous cell carcinoma and promotes invasiveness through the non-catalytic C terminus S A Carter, N A Foster, C G Scarpini, A Chattopadhyay, M R Pett, I Roberts and N Coleman Br J Cancer 2012 107: 739-747; advance online publication, July 10, 2012; 10.1038/bjc.2012.301 Abstract | Full Text A replicated association between polymorphisms near TNFα and risk for adverse reactions to radiotherapy C J Talbot, G A Tanteles, G C Barnett, N G Burnet, J Chang-Claude, C E Coles, S Davidson, A M Dunning, J Mills, R J S Murray, O Popanda, P Seibold, C M L West, J R Yarnold and R P Symonds Br J Cancer 2012 107: 748-753; advance online publication, July 5, 2012; 10.1038/bjc.2012.290 Abstract | Full Text Letter to the Editor Top Comment on ‘Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies’ D Lightsey National Council Against Health Fraud and Quackwatch Br J Cancer 2012 107: 754-755; advance online publication, July 17, 2012; 10.1038/bjc.2012.111 Full Text Corrigendum Top Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor negative breast cancer J Ohotski, J S Long, C Orange, B Elsberger, E Mallon, J Doughty, S Pyne, N J Pyne and J Edwards Br J Cancer 2012 107: 756; 10.1038/bjc.2012.352 Full Text Advertisement Take part in our reader survey for a chance to win a MacBook Air As a reader of NPG's clinical, academic and society-owned journals, we invite you to take part in a survey on your use of our journals and their associated websites.  Take the survey and be entered into a prize draw for a MacBook Air* *Terms & conditions apply   Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.